IN8bio, Inc. (INAB)

Market Cap	15.93M
Revenue (ttm)	n/a
Net Income (ttm)	-30.44M
Shares Out	81.26M
EPS (ttm)	-0.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	709,201
Open	0.2097
Previous Close	0.2081
Day's Range	0.1922 - 0.2072
52-Week Range	0.1910 - 1.7400
Beta	0.02
Analysts	Strong Buy
Price Target	3.60 (+1,735.8%)
Earnings Date	Mar 13, 2025

About INAB

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM and other cancers; and INB-100, an allogeneic product candidate, which is in Phase I clin...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 30, 2021
• Employees: 18
• Stock Exchange: NASDAQ
• Ticker Symbol: INAB
• Website: https://in8bio.com

Analyst Forecast

According to 2 analysts, the average rating for INAB stock is "Strong Buy." The 12-month stock price forecast is $3.6, which is an increase of 1,735.80% from the latest price.

Price Target

$3.6

(1,735.80% upside)

Analyst Consensus: Strong Buy